1 / 38

The effects of erythromycin on nutrient absorption in critical illness

The effects of erythromycin on nutrient absorption in critical illness. Dr Gerald Wong FANZCA FCICM Gerald Wong, Anna DiBartolomeo , Marianne Chapman, Matthew Summers, Anthony Zaknic , Max Bellon , Anne Maddox, Robert Fraser, Michael Horowitz, Adam Deane

niran
Télécharger la présentation

The effects of erythromycin on nutrient absorption in critical illness

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The effects of erythromycin on nutrient absorption in critical illness Dr Gerald Wong FANZCA FCICM Gerald Wong, Anna DiBartolomeo, Marianne Chapman, Matthew Summers, Anthony Zaknic, Max Bellon, Anne Maddox, Robert Fraser, Michael Horowitz, Adam Deane Intensive Care Unit, Royal Adelaide Hospital Discipline of Anaesthesia and Intensive Care, University of Adelaide National Health and Medical Research Council of Australia Centre for Clinical Research and Excellence in Nutritional Physiology and Outcomes, Adelaide, South Australia Department of Nuclear Medicine, Royal Adelaide Hospital

  2. Background • Gastrointestinal motility in the critically ill • Erythromycin as a prokinetic • Absorption in the small intestine

  3. Aims • Primary • Glucose absorption • Secondary • Blood glucose • Lipid absorption • Small intestinal transit

  4. Methods • Randomised, double-blinded, crossover study • Ethics Committee approval • Written informed consent from next of kin • ANZCTR number 12610000615088

  5. Methods • Study Drug = Erythromycin 200mg or Placebo from t = -20 mins to 0 min • Study feed = 60mls Ensure from t = 0 min to t = 30 mins • * Blood sample for measurement of 3-OMG and Glucose • # Breath sample for measurement of Triolein absorption

  6. Glucose absorption • 3-O-Methylglucose (3-OMG)

  7. Lipid absorption • 13C Triolein

  8. Small intestinal transit • Technetium-99m

  9. Statistics • Sample size, pilot data • Power calculation • Non parametric tests • Time points – ‘early’ and ‘overall’

  10. Results

  11. Results

  12. Results

  13. Results

  14. Results

  15. Summary • Glucose absorption • Blood glucose level • Lipid absorption • Small intestinal transit

  16. Limitations • Interim analysis • Single dose of erythromycin • Applicability to other nutrients

  17. Future directions • Additional number of subjects • Use of non-antibiotic motilides • Small intestinal biopsy

  18. Conclusion • Erythromycin has no effect on nutrient absorption in critically ill patients

  19. Motilin and the MMC

  20. Nutrient absorption in critical illness • Disordered flow of chyme • Impaired mucosal function • Splanchnichypoperfusion • Small intestinal transit time • Possible reduction in SGLT1

  21. Inclusion eligibility • Patients admitted to a tertiary referral ICU • Aged 18 years or older • Likely to remain mechanically ventilated > 72 hours • Receiving or suitable to receive post-pyloric enteral nutrition

  22. Exclusion criteria • Pregnancy • Contraindication to enteral feeding • Previous surgery on the oesophagus, stomach , or duodenum • History of diabetes mellitus • Contraindication to opiate sedation • Receiving erythromycin at antimicrobial dose • Liver dysfunction (ALT > 3x ULN)

  23. Lipid absorption (Deane, et al ClinNutr. 2010) Potential for intrasubject variability and/or inaccuracy using isotope breath tests in the critically ill. Measurement inaccuracies may occur because of impairment of (1) absorption or (2) hepatic metabolism, as well as (3) variations in endogenous CO2 production.

  24. Concerns with erythromycin • Bacterial resistance • Cardiac toxicity • Drug interactions

  25. Delayed gastric emptying in the critically ill Healthy control Critically ill patient Deane, et al. Critical Care & Resuscitation 2009

More Related